- Home
- DOMH vs CRBP Comparison
DOMH vs CRBP Comparison
Compare DOMH & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- CRBP
- Stock Information
- Founded
- DOMH 1967
- CRBP 2009
- Country
- DOMH United States
- CRBP United States
- Employees
- DOMH N/A
- CRBP N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- CRBP Health Care
- Exchange
- DOMH Nasdaq
- CRBP Nasdaq
- Market Cap
- DOMH 71.2M
- CRBP 73.4M
- IPO Year
- DOMH N/A
- CRBP N/A
- Fundamental
- Price
- DOMH $5.70
- CRBP $8.33
- Analyst Decision
- DOMH
- CRBP Strong Buy
- Analyst Count
- DOMH 0
- CRBP 10
- Target Price
- DOMH N/A
- CRBP $53.56
- AVG Volume (30 Days)
- DOMH 322.3K
- CRBP 123.5K
- Earning Date
- DOMH 08-07-2025
- CRBP 08-05-2025
- Dividend Yield
- DOMH 5.63%
- CRBP N/A
- EPS Growth
- DOMH N/A
- CRBP N/A
- EPS
- DOMH N/A
- CRBP N/A
- Revenue
- DOMH $24,891,000.00
- CRBP N/A
- Revenue This Year
- DOMH N/A
- CRBP N/A
- Revenue Next Year
- DOMH N/A
- CRBP $150.03
- P/E Ratio
- DOMH N/A
- CRBP N/A
- Revenue Growth
- DOMH 630.80
- CRBP N/A
- 52 Week Low
- DOMH $0.83
- CRBP $4.64
- 52 Week High
- DOMH $13.58
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- DOMH 63.00
- CRBP 54.09
- Support Level
- DOMH $4.90
- CRBP $8.10
- Resistance Level
- DOMH $5.59
- CRBP $9.45
- Average True Range (ATR)
- DOMH 0.50
- CRBP 0.52
- MACD
- DOMH 0.11
- CRBP -0.08
- Stochastic Oscillator
- DOMH 82.16
- CRBP 55.74
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.